

May 15, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai 400 001
BSE Scrip Code Equity: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE Symbol: MEDPLUS

Dear Sir/ Madam,

Sub: Report of the Monitoring Agency under Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR")

Pursuant to Regulation 32(6) of SEBI LODR, we attach herewith Monitoring Agency Report dated May 15, 2024 received from Axis Bank Limited, the Monitoring Agency for the quarter and year ended March 31, 2024 in respect of utilization of proceeds of Initial Public Offer ("IPO") of the Company.

This is for your information and records. The same is available on Company's website.

Thanking you,

#### For MedPlus Health Services Limited

MANOJ Digitally signed by MANOJ KUMAR SRIVASTAVA SRIVASTAVA 20:03:48 +05'30'

Manoj Kumar Srivastava Company Secretary & Compliance Officer FCS 7460

Encl: a/a

#### AXB/CO/2024-25/197 May 15, 2024

To,
Medplus Health Services Limited
H. No.-11-6-56, Survey no.257 & 258/1,
Opp IDPL Railway siding road,
Moosapet, Kukatpally Hydrebad,
Telangana -500004

Dear Sir,

## Sub: MEDPLUS HEALTH SERVICES LIMITED (the "Company") - Monitoring Agency Report

We write in our capacity of Monitoring Agent to the Company and refer to our duties cast under Regulation 41(2) of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018.

In terms of above, please find attached the Monitoring Report for the quarter ended on **March 31, 2024** as per Schedule XI of the aforesaid SEBI Regulations.

Request you to kindly take the same on records.

Thanking you.

For and on behalf of Axis Bank Ltd

Hardik Shah Date: 2024.05.15 17:55:29

**Authorized Signatory** 



#### REPORT OF THE MONITORING AGENT

Name of the Issuer: Medplus Health Services Limited

For quarter ended: March 31, 2024

Name of the monitoring Agent: Axis Bank Limited

(a) Deviation from the objects: There is no deviation.

(b) Range of Deviation\*: Not applicable

Indicate the range of percentage deviation from the amount of issue proceeds earmarked for the objects. For example, up to 10%, 10-25%, 25-50%, 50-75%, 75-100%, not ascertainable etc.

\* Range of Deviation may be computed by taking weighted average of financial deviation of each object in the ratio of issue proceeds allocated for it. Non-financial deviation may be indicated separately by way of notes.

#### Declaration:

I/We hereby declare that this report is based on the format as prescribed by SEBI (ICDR) Regulations, 2018, as amended. I/We further declare that this report provides true and fair view of the utilization of issue proceeds.

I/We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer

For and on behalf of Axis Bank Limited (in capacity as Monitoring Agent)

Hardik Shah Date: 2024.05.15 17:56.02

Authorised Signatory
Date: May 15, 2024

### 1) Issuer Details:

Name of the issuer : MEDPLUS HEALTH SERVICES LIMITED

The names of the promoters of the issuer Lone Furrow Investments Private Limited And Agilemed Investments Private Limited Industry / sector to which it belongs : Gangadi Madhukar Reddy,

: Healthcare Services

2) Issue Details:

Issue period : 13<sup>th</sup> December,2021 to 15<sup>th</sup> December,2021

Type of issue (rights) : Initial Public Offer

Type of specified security : Equity Shares

Grading : Not Applicable

Issue size (₹ in Crores) : Rs. 6000.00 million

## 3) Details of the arrangement made to ensure the monitoring of issue proceeds:

(Give item by item description for all the objects stated in offer document separately in following format)

Particulars	Reply	Comments of Monitoring Agent	Comments of Board of Directors
Whether all the utilization is as per disclosure in Offer Document?	Yes/ No	Yes	-
Whether Shareholder approval is obtained in case of material deviations from expenditures disclosed in Offer Document?	Yes/ No	Not Applicable	-
Whether means of finance for disclosed objects of the Issue has changed?	Yes/ No	No	-
Any major deviation observed over the earlier monitoring Agency reports?	Yes/ No	No	-
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes/ No	Not Applicable	-
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Yes/ No	Not Applicable	-
Any favorable events improving object(s) viability	Yes/ No	Not Applicable	_
Any unfavorable events affecting object(s) viability	Yes/ No	Not Applicable	-
Any other relevant information that may materially affect the decision making of the investors	Yes/ No	NIL	-

<sup>\*</sup>Where material deviation may be defined to mean:

- 1) Deviation in the objects or purposes for which the funds have been raised
- 2) Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.

## 4) Details of object(s) to be monitored:

(i) Cost of Objects:

(₹ in Million)

SI. No	Item Head	Source of information / certifications considered by Monitoring Agent for preparation of report	Original Cost (as per Offer Document) Amount in INR. Million	Revised Cost	Comments of Monitoring Agent	Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	Gross Proceeds from the Fresh Issue	Prospectus, Monitoring Agency Agreement &	6,000.00	NA	NA	NA	NA	NA
2	(Less) Offer expenses (only those apportioned to Issuer)	Practising Chartered Accountant certificate dated	(217.27) *	NA	NA	NA	NA	NA
	Net Proceeds		5,782.73					

<sup>\*</sup>Deduction on account of Estimated Offer Expense.

(ii) Progress in the object(s)- (Give item by item description for all the objects stated in offer document separately in following format) (in ₹)

SI No	Item Head	Amount as	Amount utilized			Total
		proposed in Offer Document Amount in Millions	As at beginning of the quarter Amount in Millions	During the quarter	At the end of the quarter Amount in Millions	unutilized amount Amount in Millions
	Investment into Material Subsidiary, Optival Health Solutions Private Limited for funding	4,671.70	4,671.70	-	4,671.70	-

working capital requirements					
General Corporate Purposes	1,111.03	428.72	19.80	448.53	662.50
Total	5,782.73	5,100.42	19.80	5,120.23	662.50

<sup>\*</sup> The figures have been converted and rounded to nearest decimal places upto two digits.

# (iii) Deployment of unutilized Issue Proceeds

(in ₹)

Type of instrument where amount invested- Fixed Deposits	Amount invested	Maturity date	Return on investment (ROI%)	Date of Deposit/Renewed Date	Market value as at the end of quarter *
HDFC Bank	4,99,99,999	30-04-2024	6.50	31-01-2024	5,04,87,499
HDFC Bank	4,00,00,000	20-04-2024	6.50	20-01-2024	4,04,60,328
HDFC Bank	2,25,00,000	29-06-2024	6.50	30-03-2024	2,25,07,193
HDFC Bank	2,10,00,000	30-04-2024	6.50	30-12-2023	2,13,12,179
HDFC Bank	29,00,00,000	07-06-2024	7.40	08-03-2024	29,12,66,492
Axis Bank Limited	5,00,00,000	19-07-2024	7.40	17-07-2023	5,23,91,272
Axis Bank Limited	3,90,00,000	14-08-2024	7.25	09-08-2023	4,06,64,296
Axis Bank Limited	5,00,00,000	14-08-2024	7.25	09-08-2023	5,21,33,712
Axis Bank Limited	5,00,00,000	14-08-2024	7.25	09-08-2023	5,21,33,711
Axis Bank Limited	5,00,00,000	03-04-2025	7.40	30-03-2024	5,00,17,902
	66,24,99,999				67,33,74,584

<sup>\*</sup> Principal Plus Interest Less TDS, if any

## (iv) Delay in implementation of the object(s)- Not Applicable

Object(s)	ect(s) Completion Date		Delay (No. of days/months)	Comments of the Monitoring Agent.	
Name	per Offer Document	Actual*	days/months)	Montoring rigent.	
		NA			

(v) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document.

(in Million)

Item Head	Amount as per offer document	Amount Utilized as on 31 <sup>st</sup> March 2024	Unutilised Balance
General corporate purposes	1,111.03*	448.53	662.50

<sup>\*</sup>After adjusting estimated offer expenses